Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial

AIMS: This double‐blind, randomized, placebo‐controlled trial (http://clinicaltrials.gov NCT02453555) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg as add‐on to linagliptin (Lina) 5 mg (fixed‐dose combination, Empa/Lina 10/5 or 25/5) in insufficiently controlled Japanese type...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Kawamori, Ryuzo, Haneda, Masakazu, Suzaki, Keiko, Cheng, Gang, Shiki, Kosuke, Miyamoto, Yuki, Solimando, Fernando, Lee, Christopher, Lee, Jisoo, George, Jyothis
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6099460/
https://ncbi.nlm.nih.gov/pubmed/29766636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13352
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky